U.K. Venture Group Abingworth Attracts $375M For New Bioventures Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
The BioVentures VI fund will invest across the life sciences sector in Europe and the U.S. and could herald an uptick in VC fundraising activity.
You may also be interested in...
With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders
The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.